24 completed, 13 terminated, 4 withdrawn, 2 active not recruiting. 25 Phase 2, 18 Phase 1, 3 Not applicable, 3 Phase 3.
Follow Recurrent Non-Small Cell Lung Carcinoma: new trials by email Literature Review of Recurrent Non-Small Cell Lung Carcinoma trials Research Report on Recurrent Non-Small Cell Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Methotrexate, Pharmacokinetic Study, Regorafenib - KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Completed | Stanford University | 22 | 2018-08-14 | 2023-08-01 |
| Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads Nivolumab, Laboratory Biomarker Analysis - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-29 | 2018-04-25 | |
| Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Emory University | 2017-07-21 | 2019-05-21 | |
| Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer | Phase 2 | Unknown | Northwestern University | 17 | 2017-07-12 | 2020-10-14 |
| Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer Laboratory Biomarker Analysis, Nimotuzumab, Nivolumab - EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 7 | 2017-06-29 | 2023-10-05 |
| Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer Nivolumab, Plinabulin - ALK Gene Translocation, EGFR Activating Mutation | Phase 1 / Phase 2 | Terminated | University of Washington | 5 | 2017-06-14 | 2019-03-04 |
| Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | NRG Oncology | 218 | 2017-04-07 | 2026-06-08 |
| Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis - EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 19 | 2017-03-10 | 2024-06-28 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
| TG4010 and Nivolumab in Patients With Lung Cancer TG4010, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Completed | Megan Daly, MD | 13 | 2016-12-14 | 2025-11-10 |
| Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 43 | 2016-06-17 | 2024-01-05 |
| Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography Dexamethasone, Device for PET, Laboratory Biomarker Analysis - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 6 | 2016-06-01 | 2025-08-22 |
| Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer Binimetinib, Docetaxel, Laboratory Biomarker Analysis - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2016-06-01 | 2020-07-24 | |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | Mayo Clinic | 4 | 2016-02-05 | 2018-09-05 |
| MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer Anti-PD-L1 Monoclonal Antibody MPDL3280A, Stereotactic Body Radiation Therapy - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 1 | Terminated | Megan Daly, MD | 27 | 2015-12-03 | 2022-08-04 |
| Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Quality-of-Life Assessment, Targeted Therapy - Metastatic Neoplasm, Recurrent Neoplasm | Not applicable | Terminated | Wake Forest University Health Sciences | 110 | 2015-10-01 | 2018-07-02 |
| Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib Afatinib Dimaleate, Pembrolizumab - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 1 | Completed | Jonathan Riess | 11 | 2015-09-30 | 2024-10-16 |
| Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Cisplatin, Docetaxel, Gemcitabine Hydrochloride - Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Active not recruiting | University of Southern California | 61 | 2015-09-03 | 2026-04-29 |
| Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors Buparlisib, Cisplatin, Gemcitabine Hydrochloride - Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2015-09-01 | 2023-04-27 | |
| Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide - Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 11 | 2015-05-22 | 2021-09-13 |
Showing 20 of 44. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (44) · Adenocarcinoma of Lung (5) · Brain Neoplasms (4) · Adenocarcinoma, Bronchiolo-Alveolar (3) · Breast Neoplasms (3) · Carcinoma, Renal Cell (3) · Melanoma (3) · Pancreatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Breast Neoplasms, Male (2) · Astrocytoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Ependymoma (1) · Gallbladder Neoplasms (1)
Bronchial Neoplasms (44) · Carcinoma, Bronchogenic (44) · Lung Diseases (44) · Lung Neoplasms (44) · Neoplasms (44) · Neoplasms by Site (44) · Respiratory Tract Diseases (44) · Respiratory Tract Neoplasms (44) · Thoracic Neoplasms (44) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (11) · Carcinoma (10) · Adenocarcinoma (8) · Urogenital Diseases (5) · Brain Diseases (4)
Erlotinib Hydrochloride (8) · Nivolumab (7) · Docetaxel (5) · Paclitaxel (5) · Pemetrexed (5) · Taxes (5) · pembrolizumab (5) · Carboplatin (4) · Gemcitabine (4) · Radiosurgery (4) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Azacitidine (3) · Cisplatin (3) · Magnetic Resonance Spectroscopy (3) · Platinum (3)
National Cancer Institute (NCI) (13) · Albert Einstein College of Medicine (3) · NRG Oncology (3) · Roswell Park Cancer Institute (3) · Wake Forest University Health Sciences (3) · Mayo Clinic (2) · Megan Daly, MD (2) · University of Southern California (2) · University of Washington (2) · Barbara Ann Karmanos Cancer Institute (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Jonathan Riess (1) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1)
United States (42) · Canada (6) · Israel (2) · Saudi Arabia (1) · Switzerland (1)
Alex Adjei (2) · Karen Kelly (2) · Roman Perez-Soler (2) · Angela Alistar (1) · Anthony El-Khoueiry (1) · Anthony Shields (1) · Apar K Ganti, MD (1) · Christina Baik (1) · Chukwumere Nwogu (1) · Don Gibbons (1) · Douglas Johnson, M.D. (1) · Edward Garon (1) · Grace Dy (1) · Heather Wakelee (1)
PMID 22586682, PMID 27491498, PMID 28950351, PMID 29203590, PMID 30045932, PMID 30915273, PMID 33021871, PMID 33608212, PMID 33636454, PMID 33885704, PMID 34323922, PMID 35254001, PMID 41114938
P30CA006973 (3), P30CA012197 (3), P30CA013330 (3), P30CA015704 (3), P30CA093373 (3), U10CA180868 (3), N01CM00038 (2), P30CA014089 (2), P30CA033572 (2), U10CA021661 (2), U10CA180821 (2), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM62202 (1)